Catalytically Hyperactive Variant of Human APOBEC3G Protein


Researchers at the National Cancer Institute (NCI) have developed a highly active variant of the catalytic domain APOBEC3G with higher ssDNA affinity. This variant may be used to develop therapeutics for AIDS, and may also be used as a tool of gene editing techniques. This hyperactive variant of the human APOBEC3G protein (hereby called CTD2) can be used as a tool to edit human genes in combination with the CRISPR/Cas9 system. CTD2 is selective to a specific target DNA sequence, soluble, and catalytically hyperactive, which makes CTD2 the ideal molecule to use in the aforementioned gene editing, using the CRISPR/Cas9 system. 

Figure: Antiviral restriction activity of FLAG-NTD-CTD2

Antiviral restriction activity of FLAG-NTD-CTD2



Potential Commercial Applications: Competitive Advantages:
  • Therapeutic for HIV
  • Gene Editing
 
  • The variant of the catalytic domain of APOBEC3G has high affinity to ssDNA substrates as apparent dissociation constant, Kd, is 55 µM
  • The variant of the catalytic domain of APOBEC3G can catalyze deamination of cytosines in single stranded DNA 20 times faster than the wild type catalytic domain of APOBEC3G
  • The variant of the catalytic domain of APOBEC3G is 4 times more soluble than the wild type catalytic domain of APOBEC3G


Inventors:

Hiroshi Matsuo (NCI)  ➽ more inventions...


Intellectual Property:
Application No. 62/673,591

Publications:
Maiti A, et al. Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA.  PMID 29941968

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-150-2018
Updated: Oct 15, 2018